U.S. markets closed

Merck & Co., Inc. (MRCK34.SA)

Sao Paolo - Sao Paolo Delayed Price. Currency in BRL
Add to watchlist
435.51-0.30 (-0.07%)
At close: 4:41PM BRT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close435.81
Open435.51
Bid415.30 x 0
Ask439.50 x 0
Day's Range435.51 - 435.51
52 Week Range328.13 - 481.69
Volume10
Avg. Volume451
Market Cap1.084T
Beta (5Y Monthly)0.49
PE Ratio (TTM)106.12
EPS (TTM)4.10
Earnings DateN/A
Forward Dividend & Yield9.94 (2.28%)
Ex-Dividend DateDec 13, 2019
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • MarketWatch

      Johnson & Johnson stock outperforms market on strong trading day

      COMPANY CLOSE UPDATES Terrence Horan Shares of Johnson & Johnson JNJ inched 0.71% higher to $148.60 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.

    • MarketWatch

      Cisco, Chevron share losses contribute to Dow's 25-point fall

      DOW UPDATE Dragged down by losses for shares of Cisco and Chevron, the Dow Jones Industrial Average is declining Friday morning. The Dow (DJIA) was most recently trading 28 points (0.1%) lower, as shares of Cisco (CSCO) and Chevron (CVX) are contributing to the index's intraday decline.

    • MarketWatch

      NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment

      The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.